
FIGURE 1


Alkaline Phosphatase
120 mg
80 mg
Placebo
Change vs Baseline (U/L)
10
5
0
-5
-10
-15
-20
-25
-30
0
2
4
6
8
10
12
14
Months

2C

FIGURE 2



2B
GammaGT
Change vs Baseline (U/L)
30
20
10
0
-10
-20
-30
-40
0
2
4
6
8
10
12
14
Months
120 mg
80 mg
Placebo

FIGURE 3a




Plasma C4 evolution in patients with highest ALP levels at baseline (4th quartile)
Relative delta EP-B (%)
40
30
20
10
0
-10
-20
-30
-40
35
-18
*
-26
**
Placebo
Elafibranor 80 mg
Elafibranor 120 mg

FIGURE 3b


Plasma C4 evolution in patients with highest ALP levels at baseline (4th quartile)
Effect size (%)
0
-10
-20
-30
-40
-50
-60
-70
-53
*
-61
**
Elafibranor 80 mg
Elafibranor 120 mg